Strengthening Africa's response to Mpox (monkeypox): insights from historical outbreaks and the present global spread.

David B Olawade, Ojima Z Wada, Sandra Chinaza Fidelis, Oluwafemi S Oluwole, Chibuike S Alisi, Nifemi F Orimabuyaku, Aanuoluwapo Clement David-Olawade
Author Information
  1. David B Olawade: Department of Allied and Public Health, School of Health, Sport and Bioscience, University of East London, London, United Kingdom.
  2. Ojima Z Wada: Division of Sustainable Development, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.
  3. Sandra Chinaza Fidelis: School of Nursing and Midwifery, University of Central Lancashire, Preston Campus, United Kingdom.
  4. Oluwafemi S Oluwole: Department of Public Health, School of Health and Life Science, Teesside University, Middlesbrough, United Kingdom.
  5. Chibuike S Alisi: Department of Allied and Public Health, School of Health, Sport and Bioscience, University of East London, London, United Kingdom.
  6. Nifemi F Orimabuyaku: English Programme, Bowen University, Iwo, Osun State, Nigeria.
  7. Aanuoluwapo Clement David-Olawade: Endoscopy Unit, Glenfield Hospital, University Hospitals of Leicester, NHS Trust, Leicester, United Kingdom.

Abstract

Mpox, formerly known as Monkeypox, is a viral zoonotic disease endemic to Central and West Africa that has posed significant public health challenges since its identification in 1970. Despite decades of experience in managing outbreaks, the 2022-2024 Mpox outbreaks exposed substantial gaps in global preparedness and response, leading the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (PHEIC) in 2022. The resurgence of cases in Europe in 2022 and the more recent emergence of the virulent clade ���b in the Democratic Republic of the Congo (DRC) in 2024 have highlighted a critical need for improved proactive and response strategies to curb the epidemic. This narrative review examines the historical and recent epidemiology of Mpox in Africa and explores the factors that have limited effective management. These include objective influences such as viral mutations, zoonotic transmission patterns, and environmental changes like deforestation, as well as subjective factors, including delayed responses, limited vaccine availability, cessation of smallpox vaccinations, and inequitable access to healthcare. In particular, the review emphasizes the ongoing disparities in global health equity, as wealthier nations have been able to secure vaccines and therapeutics quickly, while endemic regions in Africa continue to struggle with limited resources. The review also discusses how socio-economic and cultural factors, combined with weak public health infrastructure and inadequate surveillance systems, perpetuate cycles of outbreak in vulnerable populations. Furthermore, the emergence of clade ���b in 2024, with its higher virulence and mortality rates among children, particularly in rural areas, underscores the urgency of addressing the evolving epidemiological landscape of Mpox. In response to these challenges, this review recommends strengthening healthcare infrastructure, enhancing surveillance systems, ensuring equitable access to vaccines and treatments, and integrating environmental management into public health strategies. Global collaboration remains essential to provide African countries with the resources and support needed to manage and prevent future outbreaks effectively. Without these measures, the world risks a prolonged public health crisis with far-reaching consequences for both Africa and the global community.

Keywords

References

  1. Lancet Infect Dis. 2019 Aug;19(8):872-879 [PMID: 31285143]
  2. Ann Intern Med. 2022 Aug;175(8):1177-1178 [PMID: 35709341]
  3. J Med Virol. 2022 Sep;94(9):4034-4036 [PMID: 35614026]
  4. J Med Microbiol. 2023 Jun;72(6): [PMID: 37378642]
  5. Trop Med Infect Dis. 2016 Dec 20;1(1): [PMID: 30270859]
  6. Infect Dis Rep. 2022 Sep 30;14(5):772-783 [PMID: 36286200]
  7. J Korean Med Sci. 2022 Jun 06;37(22):e188 [PMID: 35668692]
  8. Bull World Health Organ. 2020 Sep 1;98(9):638-640 [PMID: 33012864]
  9. Zool Res. 2022 Jul 18;43(4):612-614 [PMID: 35758536]
  10. Vaccines (Basel). 2022 Dec 15;10(12): [PMID: 36560564]
  11. Int J Environ Res Public Health. 2022 Nov 24;19(23): [PMID: 36497712]
  12. Lancet Glob Health. 2024 Oct;12(10):e1577-e1579 [PMID: 39178878]
  13. Emerg Infect Dis. 2021 Apr;27(4): [PMID: 33756100]
  14. Euro Surveill. 2024 Mar;29(11): [PMID: 38487886]
  15. Microorganisms. 2022 Aug 12;10(8): [PMID: 36014051]
  16. Trends Microbiol. 2012 Feb;20(2):80-7 [PMID: 22239910]
  17. Front Microbiol. 2022 Sep 23;13:1011049 [PMID: 36246252]
  18. Viruses. 2022 Dec 29;15(1): [PMID: 36680142]
  19. J Med Virol. 2019 Apr;91(4):533-540 [PMID: 30357851]
  20. Acta Trop. 2020 Jun;206:105450 [PMID: 32194068]
  21. Expert Rev Anti Infect Ther. 2019 Feb;17(2):129-139 [PMID: 30625020]
  22. N Engl J Med. 2022 Aug 25;387(8):679-691 [PMID: 35866746]
  23. Viruses. 2020 Nov 05;12(11): [PMID: 33167496]
  24. Pathogens. 2023 Feb 21;12(3): [PMID: 36986285]
  25. Allergy. 2023 Mar;78(3):639-662 [PMID: 36587287]
  26. Nat Med. 2024 May;30(5):1225-1226 [PMID: 38472296]
  27. Int J Environ Res Public Health. 2022 Dec 14;19(24): [PMID: 36554659]
  28. J Med Virol. 2023 Jan;95(1):e28036 [PMID: 35906185]
  29. Arch Virol. 2023 Dec 09;169(1):2 [PMID: 38070010]
  30. MMWR Morb Mortal Wkly Rep. 2023 Jan 20;72(3):68-72 [PMID: 36656790]
  31. Emerg Microbes Infect. 2022 Dec;11(1):1768-1777 [PMID: 35751396]
  32. Rev Med Virol. 2022 Nov;32(6):e2392 [PMID: 36029181]
  33. Emerg Infect Dis. 2022 Dec;28(12):2435-2445 [PMID: 36328951]
  34. J Med Virol. 2023 Jan;95(1):e28306 [PMID: 36372558]
  35. Nat Commun. 2024 Aug 28;15(1):7452 [PMID: 39198414]
  36. Turk J Emerg Med. 2023 Jan 02;23(1):5-16 [PMID: 36818951]
  37. Int J Infect Dis. 2022 Oct;123:127-130 [PMID: 36007687]
  38. J Infect Dis. 2021 Jun 4;223(11):1870-1878 [PMID: 33728469]
  39. Lancet Glob Health. 2024 Apr;12(4):e572-e588 [PMID: 38401556]
  40. PLoS One. 2024 Jul 8;19(7):e0306594 [PMID: 38976677]
  41. PLOS Glob Public Health. 2024 Jun 7;4(6):e0003171 [PMID: 38848376]
  42. Emerg Infect Dis. 2020 Feb;26(2):345-349 [PMID: 31961314]
  43. Arch Acad Emerg Med. 2022 Jul 25;10(1):e60 [PMID: 36033997]
  44. J Clin Med. 2024 Apr 12;13(8): [PMID: 38673507]
  45. Viruses. 2024 May 03;16(5): [PMID: 38793608]
  46. Am J Trop Med Hyg. 2024 Feb 6;110(3):561-568 [PMID: 38320310]
  47. Acta Trop. 2023 Sep;245:106960 [PMID: 37276922]
  48. Viruses. 2022 Sep 29;14(10): [PMID: 36298710]
  49. Infect Genet Evol. 2022 Nov;105:105372 [PMID: 36202208]
  50. Disaster Med Public Health Prep. 2023 Aug 29;17:e464 [PMID: 37642333]
  51. Emerg Infect Dis. 2023 Mar;29(3):644-646 [PMID: 36732066]
  52. J Paediatr Child Health. 2022 Sep;58(9):1532-1538 [PMID: 35979896]
  53. Emerg Infect Dis. 2017 Dec;23(13): [PMID: 29155663]
  54. Front Cell Infect Microbiol. 2023 Jan 13;12:1083234 [PMID: 36710983]
  55. BMC Genom Data. 2023 Nov 16;24(1):67 [PMID: 37968621]
  56. PLoS Negl Trop Dis. 2019 Oct 16;13(10):e0007791 [PMID: 31618206]
  57. PLoS Negl Trop Dis. 2022 Feb 11;16(2):e0010141 [PMID: 35148313]
  58. Clin Microbiol Infect. 2024 Aug;30(8):1061-1066 [PMID: 38588877]
  59. Front Public Health. 2023 May 19;11:1141742 [PMID: 37275485]
  60. Life (Basel). 2022 Oct 12;12(10): [PMID: 36295025]
  61. Vaccine. 2020 Jul 14;38(33):5077-5081 [PMID: 32417140]
  62. Viruses. 2022 Sep 23;14(10): [PMID: 36298667]
  63. Front Public Health. 2023 Jan 12;10:1060678 [PMID: 36711326]
  64. Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2220415120 [PMID: 36787354]
  65. Pathogens. 2023 Sep 11;12(9): [PMID: 37764961]
  66. Clin Microbiol Infect. 2024 Sep;30(9):1092-1094 [PMID: 38697394]
  67. Nat Med. 2024 Oct;30(10):2791-2795 [PMID: 38871006]
  68. Viruses. 2022 Aug 27;14(9): [PMID: 36146705]
  69. JAMA. 2024 Oct 1;332(13):1045-1046 [PMID: 39163302]
  70. Rev Environ Health. 2023 Jan 02;39(2):363-370 [PMID: 36593124]
  71. Pathog Glob Health. 2024 Feb;118(1):25-32 [PMID: 37715739]
  72. Viruses. 2022 Sep 11;14(9): [PMID: 36146818]
  73. Front Public Health. 2018 Sep 04;6:241 [PMID: 30234087]
  74. MMWR Morb Mortal Wkly Rep. 2022 Aug 12;71(32):1023-1028 [PMID: 35951495]
  75. Cell. 2024 Oct 24;: [PMID: 39454573]
  76. MMWR Morb Mortal Wkly Rep. 2018 Mar 16;67(10):306-310 [PMID: 29543790]
  77. BMJ Glob Health. 2022 Aug;7(8): [PMID: 35973747]
  78. Trop Med Infect Dis. 2022 Oct 03;7(10): [PMID: 36288024]
  79. F1000Res. 2022 Nov 21;11:1360 [PMID: 36545374]
  80. Science. 2022 Jul 19;:eadd9651 [PMID: 35857487]
  81. Vaccine. 2024 Mar 7;42(7):1841-1849 [PMID: 38311533]
  82. N Engl J Med. 2022 Nov 10;387(19):1783-1793 [PMID: 36286263]
  83. Sci Rep. 2021 Jun 22;11(1):13085 [PMID: 34158533]
  84. IJID Reg. 2024 Jul 01;12:100397 [PMID: 39140010]
  85. Vaccines (Basel). 2022 Sep 15;10(9): [PMID: 36146612]
  86. Clin Microbiol Infect. 2023 Dec;29(12):1502-1507 [PMID: 37507009]
  87. Nat Microbiol. 2024 Jun;9(6):1408-1416 [PMID: 38724757]
  88. Int J Mol Sci. 2022 Jul 17;23(14): [PMID: 35887214]
  89. PLoS One. 2019 Apr 17;14(4):e0214229 [PMID: 30995249]
  90. Public Health Pract (Oxf). 2022 Sep 12;4:100312 [PMID: 36133748]
  91. PLoS Pathog. 2022 Sep 22;18(9):e1010768 [PMID: 36136979]
  92. Rev Med Virol. 2024 May;34(3):e2541 [PMID: 38743385]
  93. Travel Med Infect Dis. 2023 Mar-Apr;52:102559 [PMID: 36809829]
  94. Med J Aust. 2022 Aug 15;217(4):193-194 [PMID: 35842889]

Word Cloud

Created with Highcharts 10.0.0MpoxhealthAfricapublicoutbreaksglobalresponsereviewfactorslimitedmanagementsystemsviralzoonoticendemicchallengesHealth2022recentemergenceclade���b2024strategieshistoricalenvironmentalaccesshealthcarevaccinesresourcesinfrastructuresurveillancediseasesformerlyknownMonkeypoxdiseaseCentralWestposedsignificantsinceidentification1970Despitedecadesexperiencemanaging2022-2024exposedsubstantialgapspreparednessleadingWorldOrganizationWHOdeclarePublicEmergencyInternationalConcernPHEICresurgencecasesEuropevirulentDemocraticRepublicCongoDRChighlightedcriticalneedimprovedproactivecurbepidemicnarrativeexaminesepidemiologyexploreseffectiveincludeobjectiveinfluencesmutationstransmissionpatternschangeslikedeforestationwellsubjectiveincludingdelayedresponsesvaccineavailabilitycessationsmallpoxvaccinationsinequitableparticularemphasizesongoingdisparitiesequitywealthiernationsablesecuretherapeuticsquicklyregionscontinuestrugglealsodiscussessocio-economicculturalcombinedweakinadequateperpetuatecyclesoutbreakvulnerablepopulationsFurthermorehighervirulencemortalityratesamongchildrenparticularlyruralareasunderscoresurgencyaddressingevolvingepidemiologicallandscaperecommendsstrengtheningenhancingensuringequitabletreatmentsintegratingGlobalcollaborationremainsessentialprovideAfricancountriessupportneededmanagepreventfutureeffectivelyWithoutmeasuresworldrisksprolongedcrisisfar-reachingconsequencescommunityStrengtheningAfrica'smonkeypox:insightspresentspreadEmerginginfectiousOutbreakSurveillanceZoonotic

Similar Articles

Cited By (1)